Metagenomi Therapeutics (MGX) Revenue (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Revenue for 4 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Revenue fell 69.76% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $22.3 million, a 50.66% decrease from a year earlier, with the FY2025 full-year figure at $25.2 million, down 51.79% from the prior year.
• Revenue was $1.2 million for Q1 2026 at Metagenomi Therapeutics, down from $3.9 million in the prior quarter.
• Over five years, Revenue peaked at $20.0 million in Q2 2024 and troughed at $1.2 million in Q1 2026.
• A 4-year average of $9.5 million and a median of $9.6 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 76.48% in 2024 and tumbled 69.76% in 2026, its largest moves.
• Over 4 years, Revenue stood at $12.4 million in 2023, then declined by 22.46% to $9.6 million in 2024, then tumbled by 59.32% to $3.9 million in 2025, then tumbled by 68.09% to $1.2 million in 2026.
• The last three Revenue figures came in at $1.2 million (Q1 2026), $3.9 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.